Genetic Variants Associated with Unexplained Sudden Cardiac Death
By LabMedica International staff writers Posted on 22 Jun 2021 |

Image: Genetic variants are associated with unexplained sudden cardiac death in both adult White and African American individuals (Photo courtesy of Latin American Society of Interventional Cardiology)
As many as 450,000 Americans die every year from a sudden, fatal heart condition, and in slightly more than one in ten cases the cause remains unexplained even after an autopsy. Most sudden cardiac deaths are caused by abnormal heart rhythms called arrhythmias and the most common life-threatening arrhythmia is ventricular fibrillation.
Unexplained sudden cardiac death (SCD) describes SCD with no cause identified. Genetic testing helps to diagnose inherited cardiac diseases in unexplained SCD. However, the associations between pathogenic or likely pathogenic (P/LP) variants of inherited cardiomyopathies (CMs) and arrhythmia syndromes have never been systematically examined.
Cardiovascular Scientists at the University of Maryland School of Medicine (Baltimore, MD, USA) and their many colleagues performed genetic sequencing in 413 patients, who died at age 41 on average of sudden unexplained heart failure. This genetic association study included 683 African American and White adults who died of unexplained SCD and were included in an autopsy registry. Overall, 413 individuals had DNA of acceptable quality for genetic sequencing. Data were collected from January 1995 to December 2015. A total of 30 CM genes and 38 arrhythmia genes were sequenced, and variants in these genes, curated as P/LP, were examined to study their frequency.
The team reported that the median (interquartile range) age at death of the 413 included individuals was 41 (29-48) years, 259 (62.7%) were men, and 208 (50.4%) were African American adults. A total of 76 patients (18.4%) with unexplained SCD carried variants considered P/LP for CM and arrhythmia genes. In total, 52 patients (12.6%) had 49 P/LP variants for CM, 22 (5.3%) carried 23 P/LP variants for arrhythmia, and two (0.5%) had P/LP variants for both CM and arrhythmia.
Overall, 41 P/LP variants for hypertrophic CM were found in 45 patients (10.9%), nine P/LP variants for dilated CM were found in 11 patients (2.7%), and 10 P/LP variants for long QT syndrome were found in 11 patients (2.7%). No significant difference was found in clinical and heart characteristics between individuals with or without P/LP variants. African American and White patients were equally likely to harbor P/LP variants.
Aloke Finn, MD, Clinical Associate Professor of Medicine and the senior author of the study, said, “Genetic screening isn't routinely used in cardiology, and far too many patients still die suddenly from a heart condition without having any previously established risk factors. We need to do more for them. What we found opens the door and asks some important questions. Should we be doing routine genetic screening in those who have a family history of unexplained sudden cardiac death?”
The authors concluded that in this large genetic association study of community cases of unexplained SCD, nearly 20% of patients carried P/LP variants, suggesting that genetics may contribute to a significant number of cases of unexplained SCD. The findings regarding both the association of unexplained SCD with CM genes and race-specific genetic variants suggest new avenues of study for this poorly understood entity. The study was published on June 2, 2021 in the journal JAMA Cardiology.
Related Links:
University of Maryland School of Medicine
Unexplained sudden cardiac death (SCD) describes SCD with no cause identified. Genetic testing helps to diagnose inherited cardiac diseases in unexplained SCD. However, the associations between pathogenic or likely pathogenic (P/LP) variants of inherited cardiomyopathies (CMs) and arrhythmia syndromes have never been systematically examined.
Cardiovascular Scientists at the University of Maryland School of Medicine (Baltimore, MD, USA) and their many colleagues performed genetic sequencing in 413 patients, who died at age 41 on average of sudden unexplained heart failure. This genetic association study included 683 African American and White adults who died of unexplained SCD and were included in an autopsy registry. Overall, 413 individuals had DNA of acceptable quality for genetic sequencing. Data were collected from January 1995 to December 2015. A total of 30 CM genes and 38 arrhythmia genes were sequenced, and variants in these genes, curated as P/LP, were examined to study their frequency.
The team reported that the median (interquartile range) age at death of the 413 included individuals was 41 (29-48) years, 259 (62.7%) were men, and 208 (50.4%) were African American adults. A total of 76 patients (18.4%) with unexplained SCD carried variants considered P/LP for CM and arrhythmia genes. In total, 52 patients (12.6%) had 49 P/LP variants for CM, 22 (5.3%) carried 23 P/LP variants for arrhythmia, and two (0.5%) had P/LP variants for both CM and arrhythmia.
Overall, 41 P/LP variants for hypertrophic CM were found in 45 patients (10.9%), nine P/LP variants for dilated CM were found in 11 patients (2.7%), and 10 P/LP variants for long QT syndrome were found in 11 patients (2.7%). No significant difference was found in clinical and heart characteristics between individuals with or without P/LP variants. African American and White patients were equally likely to harbor P/LP variants.
Aloke Finn, MD, Clinical Associate Professor of Medicine and the senior author of the study, said, “Genetic screening isn't routinely used in cardiology, and far too many patients still die suddenly from a heart condition without having any previously established risk factors. We need to do more for them. What we found opens the door and asks some important questions. Should we be doing routine genetic screening in those who have a family history of unexplained sudden cardiac death?”
The authors concluded that in this large genetic association study of community cases of unexplained SCD, nearly 20% of patients carried P/LP variants, suggesting that genetics may contribute to a significant number of cases of unexplained SCD. The findings regarding both the association of unexplained SCD with CM genes and race-specific genetic variants suggest new avenues of study for this poorly understood entity. The study was published on June 2, 2021 in the journal JAMA Cardiology.
Related Links:
University of Maryland School of Medicine
Latest Pathology News
- Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
- AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
- AI-Driven Analysis of Digital Pathology Images to Improve Pediatric Sarcoma Subtyping
- AI-Based Model Predicts Kidney Cancer Therapy Response
- Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
- World’s First AI Model for Thyroid Cancer Diagnosis Achieves Over 90% Accuracy
- Breakthrough Diagnostic Approach to Significantly Improve TB Detection
- Rapid, Ultra-Sensitive, PCR-Free Detection Method Makes Genetic Analysis More Accessible
- Spit Test More Accurate at Identifying Future Prostate Cancer Risk
- DNA Nanotechnology Boosts Sensitivity of Test Strips
- Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
- New Error-Corrected Method to Help Detect Cancer from Blood Samples Alone
- "Metal Detector" Algorithm Hunts Down Vulnerable Tumors
- Novel Technique Uses ‘Sugar’ Signatures to Identify and Classify Pancreatic Cancer Cell Subtypes
- Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
- AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Channels
Clinical Chemistry
view channel
AI-Powered Blood Test Accurately Detects Ovarian Cancer
Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more
Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. Introducing a flexible, decentralized sequencing system at the... Read moreMass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more
First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
In the United States, syphilis cases have surged by nearly 80% from 2018 to 2023, with 209,253 cases recorded in the most recent year of data. Syphilis, which can be transmitted sexually or from mother... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read more
New Test Diagnoses Bacterial Meningitis Quickly and Accurately
Bacterial meningitis is a potentially fatal condition, with one in six patients dying and half of the survivors experiencing lasting symptoms. Therefore, rapid diagnosis and treatment are critical.... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more